AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00890526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Sound Therapy
Description: The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
Study NCT00890526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sound Therapy
Description: The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
Study NCT02489526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: standard treatment, up to 6 cycles
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: standard treatment, up to 6 cycles
Study NCT02489526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive the corresponding amount of placebo.
Study NCT01458561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFoam Surgical Matrix
Description: Surgical adjunct to control bleeding in open liver surgery
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: standard treatment, up to 6 cycles
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: standard treatment, up to 6 cycles
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: standard treatment, up to 6 cycles
Study NCT02379325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lets Quit
Description: Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling.
Study NCT02379325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lets Quit
Description: Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling.
Study NCT02379325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pamphlets material
Description: Given pamphlets material on smoking and complication
Study NCT02379325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pamphlets material
Description: Given pamphlets material on smoking and complication
Study NCT01220414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, then placebo
Description: 50 mg of naltrexone
Study NCT01458561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam Plus
Description: Surgical adjunct in control of bleeding in open liver surgery
Study NCT01777347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Saline
Description: Two 4 mL nebulization of 3% saline with 20 minutes interval
Study NCT01220414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then Naltrexone
Description: sugar pill
Study NCT02310048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-FormA
Study NCT02310048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-FormB
Study NCT02507479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Chemotherapy given prior to allogeneic stem cell transplantation
Study NCT01734876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tactile Touch
Description: Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
Study NCT01734876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile Touch
Description: Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
Study NCT01734876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest To Music
Description: Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
Study NCT01734876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest To Music
Description: Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
Study NCT04764435 — intervention group
Intervention type: OTHER
Intervention: Physician ownership
Description: The intervention or exposure is whether the dialysis facility was owned by a physician in 2017
Study NCT01777347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
Study NCT04764435 — intervention group
Intervention type: OTHER
Intervention: Large dialysis organization ownership
Description: The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017
Study NCT01424592 — intervention group
Intervention type: DEVICE
Intervention: Testing with a portable sleep apnea monitor .
Description: Portable sleep apnea testing will performed on referred patients.
Study NCT01536574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Requip PR
Description: Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
Study NCT01216839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
Study NCT02108119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT02108119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Study NCT03210480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium sulphate prolonged-release 660 mg
Description: Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
Study NCT03210480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium carbonate immediate-release 150 mg and 300 mg
Description: Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
Study NCT03569761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer Screening Decision Aid
Description: Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
Study NCT03569761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
Study NCT03060694 — intervention group
Intervention type: OTHER
Intervention: diabetes
Description: 1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%.
Study NCT03808064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV home visit
Description: Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
Study NCT03173391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: BID Oral administration
Study NCT03173391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID Oral administration
Study NCT02973763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib
Study NCT01805180 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)
Description: In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
Study NCT01805180 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)
Description: In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
Study NCT04274348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies and blood samples
Description: Two skin biopsies and 30 ml of blood will be collected.
Study NCT04068857 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
Study NCT04068857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
Study NCT05246540 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT01400932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI148512
Description: GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
Study NCT01400932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
Study NCT02933918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Safety of nasal irrigation with probiotics in healthy volunteers
Study NCT03105739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMA removal
Description: According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
Study NCT03105739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA removal
Description: According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
Study NCT01860560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Therapy
Description: Blower-based High Flow Therapy delivered by nasal cannula
Study NCT01860560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
Study NCT01846455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
Study NCT01846455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
Study NCT01846455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
Study NCT01846455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
Study NCT04261530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Study NCT04261530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music/self-care
Study NCT04261530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care
Study NCT00724542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose tablets
Description: 0.2mg Tid
Study NCT04261530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education
Study NCT02427282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miniscrew-supported Frog molar distalizing appliance
Description: miniscrew 10mm length and 1.7mm diameter FORESTADENT company
Study NCT02427282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Frog molar distalizing appliance
Description: Nance buttons attached to first premolars band
Study NCT04507009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: topical gaseous ozone application
Study NCT04507009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGF
Description: concentrated growth factor (CGF) application
Study NCT04507009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: Alvogyl application
Study NCT04092842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone prosthesis
Description: Silicone prosthesis
Study NCT04092842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: Usual surgery
Study NCT00595231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN111
Description: 500 mg for 1 week followed by 1000 mg for 7 weeks
Study NCT00595231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg tablets
Study NCT01993888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST® Fibrin Sealant Patch
Study NCT01993888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Study NCT05317767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [Inactivated split influenza vaccine]
Description: solution for intramuscular injection, 0.5 ml
Study NCT05317767 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Split Influenza Vaccine
Description: solution for intramuscular injection, 0.5 ml
Study NCT04222283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
Study NCT00806221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emollient (Cetaphil cream)
Description: Cetaphil cream applied daily from birth
Study NCT00999830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101
Description: One infusion of IPH2101 every 4 weeks
Study NCT00003200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study NCT00003200 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT04321811 — intervention group
Intervention type: OTHER
Intervention: Observation of patients with known, suspected, or at risk for COVID-19 infection
Description: Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
Study NCT01200433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
Study NCT01200433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
Study NCT00832819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
Study NCT00832819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
Study NCT03250286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS
Description: Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed.
Study NCT00832819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
Study NCT00832819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
Study NCT03993717 — intervention group
Intervention type: BIOLOGICAL
Intervention: SHINGRIX
Description: A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm